Compare OneSpan Inc (OSPN) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
OneSpan Inc vs ResMed Inc. — how do they compare? OneSpan Inc trades at $18.25 (market cap $662.97M), while ResMed Inc. trades at $230.46 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 48.1× OneSpan Inc's market cap, and OneSpan Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold OneSpan Inc for 18 Days and ResMed Inc. for 51 Days on average.
| OSPN | RMD | |
|---|---|---|
Market Cap | $662.97M | $31.89B |
Volume | 616,882 | 618,314 |
Sector | Technology | Health |
52-Week High | $18.42 | $277.88 |
52-Week Low | $10.15 | $182.82 |
Typical Hold Time | 18 Days | 51 Days |
Enterprise Value | $632.05M | $31.24B |
Dividend Yield | 2.89% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $17.70, down 3.7% in the last session, but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal with support at $17 and resistance at $18. Recent Q2 2026 results exceeded expectations with EPS of $0.30 versus $0.231 expected, while the company introduced new authentication technology to drive future growth.
The outlook remains positive given strong analyst support (66.7% buy ratings) and solid financial metrics, though investors should monitor declining cash flow trends and competitive pressures in the cybersecurity sector. The stock presents value opportunity with P/E of 10.16 and ROE of 26.51%, but faces execution risks in maintaining subscription revenue growth.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About OneSpan Inc
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
